A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia

  title={A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia},
  author={Ruth L. Knight and Mizanur R. Khondoker and Nicholas Magill and Robert J Stewart and Sabine Landau},
  journal={Dementia and Geriatric Cognitive Disorders},
  pages={131 - 151}
Background: Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia. In routine clinical practice, dementia is often monitored via the Mini-Mental State Examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these drugs on MMSE scores. Summary: Eighty trials were identified. Pooled effect estimates were in favour of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia subtype was a… 

Figures and Tables from this paper

Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer’s Disease: A Systematic Review and Meta-Analysis

A systematic review and meta-analysis of 284 screened abstracts indicated that AChEIs were significantly more effective than placebo in both groups and had a positive therapeutic effect compared with placebo regardless of APOE ε4 carrier status.

Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia

Among older people with dementia, treatment with AChEIs was associated with a slower cognitive decline and with reduced mortality, after a mean follow-up of almost eight years, which supports the effectiveness of A cholinesterase-inhibitors in older patients affected by these types of dementia.

Antidiabetic Drugs in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review

Intranasal insulin, pioglitazone, metformin, and liraglutide are promising drugs that could be useful in the treatment of AD, however, many questions remain to be answered in future studies, so no particular antidiabetic drug can currently be recommended to treat AD.

Is Ketogenic Diet Therapy a Remedy for Alzheimer’s Disease or Mild Cognitive Impairments?: A Narrative Review of Randomized Controlled Trials

Clinical studies mainly provide evidence of improved verbal memory, attention, and total cognitive function in ketogenic diets, but optimal procedures have not yet been clarified and ketogenic diet practices in older adults may pose several risks in long term.

Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease

  • R. Cacabelos
  • Biology, Medicine
    Expert opinion on drug metabolism & toxicology
  • 2020
The most relevant genes influencing AChEI efficacy and safety are APOE and CYPs, and APOE-4 carriers are the worst responders to A ChEIs.

Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment

ChEI use or non-use was not related to cognitive change at a 1-year follow-up visit in patients with or without amyloid burden and could not predict disease progression to CDR 1 at 1- year follow- up visit.

Influence of Acetylcholine Esterase Inhibitors and Memantine, Clinically Approved for Alzheimer’s Dementia Treatment, on Intestinal Properties of the Mouse

The findings indicate that all AD symptomatic drugs have the potential to affect distinct intestinal functions and with this—directly or indirectly—microbial commensals.

Use of Antipsychotics in Patients with Behavioral and Psychological Symptoms of Dementia: Results of a Spanish Delphi Consensus

Wide consensus was reached about the importance of early identification of BPSD in persons with cognitive impairment, the use and management of atypical antipsychotic drugs and their favorable impact on patients and caregiver’s quality of life.



A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.

The modest beneficial effects of anti-dementia drugs on cognition are independent from dementia severity, and Memantine is more effective on functional incompetence only in severe patients.

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

This systematic review systematically evaluates the evidence for the effectiveness of these 5 drugs in improving outcomes in cognition, global function, behavior, and quality of life among patients with dementia.

Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300)

In patients with mild to moderate vascular dementia, memantine 20 mg/d improved cognition consistently across different cognitive scales, with at least no deterioration in global functioning and behavior.

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)

At endpoint, memantine was shown to improve cognition relative to placebo in VaD: the change of ADAS-cog from baseline differed by a mean of −1.75 points, while CGI-C ratings showed no significant differences between treatment groups.

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Cholinesterase inhibitors and memantine are able to stabilize or slow decline in cognition, function, behavior, and global change.

Does Serotonin Augmentation Have Any Effect on Cognition and Activities of Daily Living in Alzheimer's Dementia?: A Double-Blind, Placebo-Controlled Clinical Trial

Concomitant use of selective serotonin-enhancing agents and acetyl cholinesterase inhibitors can provide greater benefit in activities of daily living and global functioning in patients with cognitive impairment.

Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials

A meta-analysis supports memantine’s clinically relevant efficacy in patients with moderate to severe AD, and shows statistically significant effects for memantine in each domain.

Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.

The study did not meet proof of concept criteria: since neither AZD3480 nor donepezil were statistically significantly superior to placebo on ADAS-Cog and was considered to be inconclusive.

Factors Associated with Response to Acetylcholinesterase Inhibition in Dementia: A Cohort Study from a Secondary Mental Health Care Case Register in London

Changes in cognitive trajectories around AChEI initiation were similar to those reported in randomised controlled trials, and the magnitude of the difference in slopes was related to level of cognitive function at treatment initiation, vascular comorbidity and antipsychotic use.